Department of Pediatrics, Obstetrics and Reproductive Medicine, Institute of Obstetrics and Gynecology, University of Siena, Siena, Italy.
Fertil Steril. 2011 Oct;96(4):917-20. doi: 10.1016/j.fertnstert.2011.07.1089. Epub 2011 Aug 16.
To compare the efficacy of two regimens (21 active pills + 7 placebo pills vs. 24 active pills + 4 placebo pills) of combined oral contraception (COC), both containing 20 μg of ethinyl E(2) and 3 mg of drospirenone, in improving the severity of pure menstrual migraine without aura.
Prospective randomized study.
Patients attending the gynecology department of the University of Siena for consultation regarding an appropriate contraception.
PATIENT(S): Women ages 20 to 35 years (n = 60) suffering from pure menstrual migraine without aura.
INTERVENTION(S): Three months of contraceptive use (ethinyl E(2) 20 μg/drospirenone 3 mg) in two different regimens: group A received 21 active + 7 placebo pills whereas group B received 24 active + 4 placebo pills.
MAIN OUTCOME MEASURE(S): Monthly evaluation of the duration and severity of patients' daily headache attacks.
RESULT(S): Although both study groups demonstrated significant reduction in the intensity and duration of menstrual migraine, patients in group B (24/4 COC) reported a significant reduction in the intensity and a shorter duration of their menstrual migraine, compared with group A (21/7 COC).
CONCLUSION(S): The 24/4 COC regimen is recommended as the preferred treatment for patients suffering from pure menstrual migraine without aura.
比较两种复方口服避孕药（COC）方案（含 20μg 炔雌醇和 3mg 屈螺酮的 21 片活性药片+7 片安慰剂片与 24 片活性药片+4 片安慰剂片）对改善无先兆性单纯月经性偏头痛严重程度的疗效。
前瞻性随机研究。
意大利锡耶纳大学妇科门诊就诊的患者，咨询合适的避孕方法。
年龄 20 至 35 岁（n=60）、患有无先兆性单纯月经性偏头痛的女性。
3 个月的避孕（炔雌醇 20μg/屈螺酮 3mg）使用两种不同方案：A 组给予 21 片活性+7 片安慰剂，B 组给予 24 片活性+4 片安慰剂。
每月评估患者日常头痛发作的持续时间和严重程度。
尽管两组研究对象的月经性偏头痛严重程度和持续时间均显著降低，但与 A 组（21/7 COC）相比，B 组（24/4 COC）患者的偏头痛强度和月经性偏头痛持续时间明显降低。
24/4 COC 方案被推荐为治疗无先兆性单纯月经性偏头痛的首选治疗方法。
